---
layout: post
title: "Revocation of Emergency Use of a Drug Product During the COVID-19 Pandemic; Availability"
date: 2026-02-05 19:08:36 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2024-05085
original_published: 2024-03-11 00:00:00 +0000
significance: 8.00
---

# Revocation of Emergency Use of a Drug Product During the COVID-19 Pandemic; Availability

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** March 11, 2024 00:00 UTC
**Document Number:** 2024-05085

## Summary

The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorization (EUA) (the Authorization) issued to Eli Lilly and Co. (Lilly), for bamlanivimab and etesevimab administered together. FDA revoked the Authorization on December 14, 2023, under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The revocation, which includes an explanation of the reasons for the revocation, is reprinted in this document.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2024/03/11/2024-05085/revocation-of-emergency-use-of-a-drug-product-during-the-covid-19-pandemic-availability)
- API: https://www.federalregister.gov/api/v1/documents/2024-05085

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
